Exprodo Software supports the world’s most in-depth study into the early signs of Alzheimer’s disease

Today see’s the launch of the world’s most in-depth study into the early signs of Alzheimer’s disease. The £6.9 million study funded by the National Institute for Health Resarch and the Medical Research Council will involve 19 organizations including Exprodo Software. The study will conduct the largest range of tests ever conducted to help identify early stages of Alzheimer’s disease. http://mrc.io/2b6i7O

By identifying the early stages of Alzhemier’s disease, we can design better clinical trials to help find a cure. This is exactly what the Deep and Frequent Phenotyping study, which launched today, plans on doing. http://bit.ly/2bro25T

The involvement of Exprodo Software is to manage the actions/to-do lists of all the people within the study. This is a complex task, due to the nature of the multi-site study, as well as the multiple modalities (types of data recording, such as MR, PET and others) involved. However, using our sophisticated Exprodo SDM, we will provide a system that will let the project manager see at-a-glance exactly what is happening and manage the the required actions accordingly.